- Research article
- Open Access
Persistent changes in spinal cord gene expression after recovery from inflammatory hyperalgesia: A preliminary study on pain memory
© Yukhananov and Kissin; licensee BioMed Central Ltd. 2008
Received: 06 August 2007
Accepted: 13 March 2008
Published: 13 March 2008
Previous studies found that rats subjected to carrageenan injection develop hyperalgesia, and despite complete recovery in several days, they continue to have an enhanced hyperalgesic response to a new noxious challenge for more than 28d. The study's aim was to identify candidate genes that have a role in the formation of the long-term hyperalgesia-related imprint in the spinal cord. This objective was undertaken with the understanding that the long-lasting imprint of acute pain in the central nervous system may contribute to the transition of acute pain to chronicity.
To analyze changes in gene expression when carrageenan-induced hyperalgesia has disappeared but propensity for the enhanced hyperalgesic response is still present, we determined the gene expression profile using oligo microarray in the lumbar part of the spinal cord in three groups of rats: 28d after carrageenan injection, 24h after injection (the peak of inflammation), and with no injection (control group). Out of 17,000 annotated genes, 356 were found to be differentially expressed compared with the control group at 28d, and 329 at 24h after carrageenan injection (both groups at p < 0.01). Among differentially expressed genes, 67 (39 in 28d group) were identified as being part of pain-related pathways, altered in different models of pain, or interacting with proteins involved in pain-related pathways. Using gene ontology (GO) classification, we have identified 3 functional classes deserving attention for possible association with pain memory: They are related to cell-to-cell interaction, synaptogenesis, and neurogenesis.
Despite recovery from inflammatory hyperalgesia, persistent changes in spinal cord gene expression may underlie the propensity for the enhanced hyperalgesic response. We suggest that lasting changes in expression of genes involved in the formation of new synapses and neurogenesis may contribute to the transition of acute pain to chronicity.
Pain that persists well beyond the healing of the injury, including surgical wounds, is a major clinical problem . Multiple mechanisms are likely responsible for persistent postinjury pain; some may be related to the transition of acute pain to chronicity, a concept that is supported by reports of the relationship between the intensity of acute postoperative pain and subsequent development of chronic pain after surgery [2–4]. A long-lasting imprint of acute pain may contribute to its transition to chronic pain. In the rat model, acute pain and hyperalgesia following an inflammation disappeared within a few days, but enhanced sensitivity to a new noxious challenge (inflammation) may persist for a very long time [5, 6]. Our previous experiments with repeated injections of carrageenan into the hindpaws demonstrated that, well after recovery (2 to 4 weeks later) from hyperalgesia induced by the initial inflammation, repeated-crossover carrageenan injection causes a distant (in contralateral hindpaw) hyperalgesia that was absent after the initial injection. The acute pain and hyperalgesia following an injection of carrageenan disappears within a few days, but despite recovery the enhanced response to a new noxious challenge may persist for a very long time [5, 7]. This phenomenon was viewed as an indication of the long-lasting imprint of acute pain in the CNS .
It seems plausible that the transition to chronic pain involved modification of gene expression within the spinal cord, which might be a mechanism of long-term imprinting of pain hypersensitivity. However, the picture of gene expression alterations and their role in control of acute and chronic pain is far from clear [8–10]. Multiple pathways seems to be involved, and their elucidation will require global profile studies of gene expression using different models of acute and chronic pain with and without drug intervention. We have found no studies on changes in gene expression long after recovery from inflammatory hyperalgesia. The aim of this study was to characterize changes in gene expression when animals are long recovered from hyperalgesia but have maintained a propensity for enhanced hyperalgesic response. We hypothesized that following the recovery from inflammatory hyperalgesia there were persistent changes in spinal cord gene expression.
The number of probe set selected according to p-value.
28d vs control
24h vs control
Ontologic classification of genes differentially expressed at 24h and 28d (B).
Number of sequences
% of total
eukaryotic 43S preinitiation complex
eukaryotic 48S initiation complex
posttranslational protein folding
chaperone cofactor dependent protein folding
response to unfolded protein
response to stress
signal transduction inhibitor
Ontologic classification of genes differentially expressed at 28d.
Number of sequences
% of total
regulation of cell proliferation
regulation of apoptosis
negative regulation of apoptosis
calcium ion binding
transmission of nerve impulse
actin polymerization and/or depolymerization
cytoskeleton organization and biogenesis
Genes differentially expressed 24h or 28d following carrageenan injection and known to be involved in pain.
1. Membrane receptors and their ligands
5-hydroxytryptamine (serotonin) receptor 1b
vasoactive intestinal peptide receptor 1
galanin receptor 1
neuropeptide y receptor y1
adenosine a1 receptor
5-hydroxytryptamine (serotonin) receptor 3a
neurotensin receptor 2
calcitonin-related polypeptide, beta
glutamate receptor, ionotropic, ampa1 (alpha 1)
glutamate receptor, metabotropic 1
neuropeptide y receptor y5
2. Ion channels and regulator of ion homeostasis
potassium large conductance calcium-activated channel, subfamily m, alpha member 1
potassium voltage gated channel, shaw-related subfamily, member 2
potassium inwardly-rectifying channel subfamily J member 14
potassium voltage-gated channel, subfamily q, member 1
sodium channel, voltage-gated, type iv, beta
s100 calcium-binding protein a4
s100 calcium binding protein a9 (calgranulin b)
3. cAMP and adenylate cyclase cascade
guanine nucleotide binding protein, alpha inhibiting 2
phosphatidylinositol 4-kinase, catalytic, alpha polypeptide
phosphatidylinositol-4-phosphate 5-kinase, type ii, alpha
g-protein-coupled receptor gpr34
phospholipase c-like 1
regulator of g-protein signaling 1
regulator of g-protein signalling 10
adenylyl cyclase 8
g protein-coupled receptor associated sorting protein 1
regulator of g-protein signaling 2
regulator of g-protein signaling 4
g protein-coupled receptor 83
4. MAPK cascade
mitogen-activated protein kinase kinase kinase kinase 3
mitogen activated protein kinase 8 interacting protein
protein tyrosine phosphatase 2e
mitogen activated protein kinase kinase kinase 1
mitogen activated protein kinase kinase kinase 3
protein phosphatase 1b, magnesium dependent, beta isoform
protein phosphatase 3, catalytic subunit, alpha isoform
rab40b, member ras oncogene family
protein phosphatase 1d magnesium-dependent, delta isoform
protein tyrosine phosphatase 4a3
protein phosphatase 1, regulatory (inhibitor) subunit 14a
rab1, member ras oncogene family
rab15, member ras onocogene family
5. Growth factors and related proteins
brain derived neurotrophic factor
IGF2 binding protein 3
IGF binding protein 6
neurotrophic tyrosine kinase, receptor, type 2
6. Arachidonic acid cascade and mediators of inflammation
prostaglandin-endoperoxide synthase 2
prostaglandin d2 synthase
interleukin 6 receptor
interleukin 6 signal transducer
phospholipase a2, group 4a
tissue inhibitor of metalloproteinase 3
microtubule-associated proteins 1b
tubulin, beta 5
early growth response 1
proteasome subunit, alpha type 3
chaperonin subunit 4 (delta)
neural cell adhesion molecule 1
Several genes ("Others", group 7) did not fit in any of these groups. Gene expression of this group (Table 4) has been reported to be altered in different pain models. Annexin 3 level was increased during episodes of migraine ; microtubule-associated protein 1B was altered 7 days after chronic constriction injury (CCI) ; synaptoporin, a major synaptic vesicle protein in Adelta- and C-fibers and co-localized with calcitonin gene-related peptide (CGRP) in sensory primary afferent neurons, increased after peripheral nerve injury .
Several genes were included in group 7 based on indirect evidence of their involvement in pain regulation. Tubulin isoform beta5 interacts with vanilloid receptor (TRPV1) and is probably a downstream effector of TRPV1 activation . Chaperonin subunit 4 (cct4) involved in folding tubulin and other cytosolic proteins is included, since mutation of this protein leads to early onset sensory neuropathy . Fyn proto-oncogene phosphorylates NMDA receptors in response to pain stimuli .
The acute pain following a single injection of carrageenan disappears within a few days; however, the enhanced sensitivity to a new noxious challenge may persist for a prolonged time [5–7]. The enhanced sensitivity may contribute to posttraumatic and postsurgical persistent pain. In experiments with repeated carrageenan injections in response to the first injection into a rat's hind paw, the induced hyperalgesia was profound on the side of injection and minimal or absent in the contralateral hind paw. However, repeated injection of carrageenan into the previously noninjected hind paw resulted in pronounced hyperalgesia in the other paw. The difference between distant hyperalgesia after the initial and repeated-crossover injection of carrageenan was used as a measure of the hyperalgesia-related memory. The enhanced hyperalgesia is present even 28 days after the initial injection .
In this study we found alterations of gene expression that lasted at least 28d and were quite different from transitory changes observed 24h after injection. The genes altered at 24h include those involved in immune reaction and protein synthesis (Table 2), whereas long-lasting changes observed 28 days after injection indicate different pathways, most notably those responsible for new synapse formation (Table 3).
The observed short-term upregulation of the immune response genes concurs with earlier reports that IL-6 [20, 21] and TNF-a (tumor necrosis factor-a)  play an important role in inflammatory pain. The upregulation of these genes had previously been associated with the development of neuropathic pain as well . A similar result has been found following nerve injury and spinal cord injury (SCI). SCI induces a robust and significant increase in mRNAs of inflammatory cytokines such as TNF-a, interleukin-1β (IL-1β), and IL-6 at 1, 3, and 24 h post-injury [23–25]. We do not know whether the changes in gene expression are mediated by inflammation, pain, possible injury to the nerve, or a combination thereof.
We observed significant changes in expression of several key enzymes (3-alpha-hydroxysteroid dehydrogenase, phospholipase a2, prostaglandin d2 synthase, and COX2) involved in eicosanoid biosynthesis (Table 4, Arachidonic acid cascade and mediators of inflammation). This cascade is usually initiated by the activation of phospholipase A2 and the release of arachidonic acid (AA) . The AA is subsequently transformed by cyclooxygenase (COX) and lipoxygenase pathways to prostaglandins, thromboxane, and leukotrienes, collectively termed eicosanoids. Eicosanoid production is considerably increased during inflammation and inflammation-induced pain, and COX is the major target for nonsteroidal antiinflammatory drugs (NSAIDs). It is possible that activation of eicosanoids by inflammation/pain causes lasting changes in gene expression. NMDA receptors, which are prominently involved in activity-dependent synaptic plasticity and tonic pain , could mediate the upregulation of inflammatory factors. Inflammation-induced NMDAR activation involves phosphorylation of the NR1 and NR2B subunits in the spinal dorsal horn by fyn proto-oncogene . The downstream changes in Egr1, MAPK, and AC expression (see Table 4) can be also induced by activation of the NMDA receptor. As an alternative, activation of the neurotensin receptor can stimulate Egr1 expression and MAP kinase pathways .
We do not know whether activation of eicosanoids and MAP kinases is part of one inflammatory/pain pathway or the former is the result of inflammation and the latter is pain-induced. In any case, long-lasting changes in gene expression are unlikely to be induced by ongoing inflammation, since the majority of genes known to be involved directly in the inflammatory response have a profile with maximum changes at 24h and returning to control levels 28d following injection. No detectable changes of inflammatory cytokine genes, including those described above, were found 28d after injection. However, initial inflammatory response may contribute to long-term changes in gene expression and pain memory. A number of genes altered in the 28d group are involved in inflammation-induced potentiation of pain sensitivity. For example, dynorphin [30, 31], neuropeptide Y (NPY), and NPY (Y1) receptor  are induced in the spinal cord by peripheral inflammation. However, it is unknown whether activation of nociceptors is required.
Based on our expression data, carrageenan injection affected at least two signal transduction pathways, MAPK and cAMP/adenylyl cyclase (AC), known to regulate nociceptive signal perception and transmission. Several isoforms of MAPK are involved in regulation of acute and chronic pain both in neuron and glial cells [33, 34]. cAMP mediates many aspects of pain transmission within neuronal cells. In particular, AC isoform 8 (AC8) that couples NMDA receptor activation to cAMP signaling pathways in neurons are important in the development of persistent pain . Activation of MAPK cascade might be mediated by neurotensin receptor via Egr1, which is known to be upregulated in response to persistent inflammatory pain  and stimulates Erk1/2 phosphorylation . It is likely that an interaction between the glutamate pathway and cAMP signaling is mediated by modulation of metabotropic glutamate receptor by RGS2 and RGS4 [37, 38], which were downregulated 24h after carrageenan injection (Table 4). Based solely on our data, we cannot tell whether the trigger for long-term changes in gene expression is the initial inflammation or pain or their combination. It is also unlikely that all changes in gene expression observed in the 28d group are related to formation and maintenance of nociceptive memory. However, the prominent group (Table 3) of differentially expressed genes controls neuronal connectivity, synaptogenesis, and neurogenesis. It is known that long-term memory and plasticity in CNS depend on formation of new synapses that require synthesis of proteins responsible for cell-to-cell interaction–in particular cadherin-like protein. There is also evidence that formation of new neurons is important for memory formation and plasticity .
There is similarity in the development of long-term potentiation (LTP), long-term memory, and pain. Research indicates that central sensitization in the spinal cord has the identical mechanism to LTP . We have found that a number of genes altered at 28d were also altered in the hippocampus during LTP: brain-derived neurotrophic factor (BDNF), early growth response 1 (EGR1), CD9 antigen (CD9), neuropeptide Y receptor Y5 (NPY5R), and neuropeptide Y receptor (NPY1R) . Genes such as BDNF [13, 42], NtrkB (BDNF receptor), Egr1 , neuropeptide Y receptor, and neuregulin1 are also known to be involved in inflammation-induced pain. For example, BDNF, a known modulator of memory, was found to be altered in rat pups one day after peripheral inflammation induced by injection of Freund's complete adjuvant . We do not believe, however, that pain memory and LTP are identical phenomena but rather share some basic mechanisms. They have different anatomical substrates, and most alterations found in our study were not observed in the hippocampus following memory formation. Based on our data, pain or inflammation or a combination thereof induces dramatic changes in gene expression. Most of these changes in gene expression subside when inflammation disappears, while some of them persist and even increase 28d later. Thus, part of the pain- and inflammation-induced changes in gene expression belong to pathway(s) that remain activated long after inflammation and acute pain disappear. We can only speculate which genes whose expression increased much more at 28d than at 24h belong to these pathways. Additional experiments are needed to narrow down the list of affected pathways. Based on the results of GO analysis, proteins involved in synaptogenesis, cell-cell interaction, and the formation of new neurons are overrepresented among differentially expressed genes at 28d after carrageenan injection. Thus, we propose that pathways related to synapse formation between newly generated neurons are particularly important for "pain memory." The tentative nature of this conclusion depends on the exploratory nature of our microarray data and analysis. The selection of genes is based on a limited number of replicates and multiple comparisons, which implies that a number of genes may be false positives. We confirmed the differential expression for a few selected genes by PCR, but more research is needed to complete verification of the microarray data.
We have observed long-lasting changes in gene expression following recovery from carrageenan-induced hyperalgesia. On the basis of these data, we propose that pathways related to synapse formation are involved in the formation of pain memory.
The study was approved by the Harvard Medical Area Standing Committee on Animals, Harvard Medical School. Experiments were performed on male Sprague-Dawley rats weighing 250–300 g that were housed with a 12-h light-dark cycle and food and water available ad libitum.
Gene expression in the lumbar part of the spinal cord was compared in three groups of rats: 28d after carrageenan injection, 24h after carrageenan injection, and a control group without injection.
Inflammation was induced by injection (26-gauge needle) of 0.1 ml of 2% carrageenan (Sigma Chemical Co., St. Louis, MO) in the plantar surface of the hind paw under halothane (2%) anesthesia. The rat paw volume was measured by a plethysmometer (Paw Volume Meter; Ugo Basile). The general procedure for measuring changes in behavioral responses for microarray experiments was as follows: For several days after arrival, rats were placed in the testing environment, and during the two days preceding the experiment, pressure threshold and hind paw volumes were measured. On the experimental day, basal values were determined twice with a 30-min interval; the average value of two readings was used as a baseline. The rats were assigned randomly (blocked randomization) to one of three groups. Carrageenan was injected into the right hind paw, and the rat was decapitated 24h or 28d after injection. Paw volume was measured on both sides 2h, 4h, 24h, and 28d after each of the carrageenan injections. We assumed that pain-related memory is most likely mediated by altered gene expression both in ipsilateral and contralateral parts of the lumbar enlargement of the spinal cord. In this study we have limited the measurement of gene expression to the ipsilateral portion that is most affected by carrageenan injection.
RNA isolation and Affymetrix GeneChip processing
The spinal cord was removed under hydraulic pressure with 10-ml syringe with saline , and the lumbar enlargement was dissected into ipsi- and contralateral parts and frozen. Tissues were kept at -80°C until RNA isolation.
Total RNA was isolated by quickly homogenizing the tissue at high speed in Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The concentration of total RNA was measured by UV spectrophotometry, and RNA quality was confirmed by electrophoresis in 1% agarose gel and Agilent bioanalyzer (Agilent Technologies, Inc, Santa Clara CA). Only those samples that had a 260/280 ratio more than 1.9 and had no signs of degradation based on agarose electrophoresis were used for analysis. The RNA samples were stored at -80°C.
Gene expression analyses were performed with the Affymetrix Rat Genome 230 v.2 chip (Affymetrix, Santa Clara, CA), which contains ~31,000 probe sets including ~17,000 annotated rat genes. For each chip, RNA from the spinal cord of 3 rats was pooled to minimize interindividual variability. Pooled spinal cord RNA from the control, 24h, and 28d groups was hybridized in triplicate to the Affymetrix 230 rat microarray, so that 9 animals were used per treatment group. The labeling, hybridization, and scanning were done through the NIH Neuroscience Microarray Consortium at Affymetrix GeneChip Resource, W. M. Keck Facility, Yale University School of Medicine, according to Affymetrix protocol using recommended equipment. The DNA chips were scanned by confocal scanner. Digitized image data were processed the MAS software (version 5.0) from Affymetrix. The expression data reported in this paper have been deposited in the National Center for Biotechnology Information Gene Omnibus database.
Microarray Data Analysis
The resulting microarray data that passed quality control tests were imported into the Rosetta Resolver system for gene expression data analysis (Rosetta Biosoftware, Kirkland, WA). While it was imported, the microarray data were subjected to background correction, intrachip normalization, and the Rosetta Resolver system Affymetrix GeneChip error model. The intensity profiles that are generated were used to build ratios with Rosetta Resolver Ratio Builder. Briefly, the first step in data analysis includes validation of each probe set based on empirical error distribution and removal of the probe pairs that are beyond three standard deviations from the mean. Probe-level data were used to increase robustness by calculating the averages. The expression values for individual profiles were combined using an error-weighted average in a transformed space, and the error of the result was adjusted correspondingly. All profiles belonging to one single experiment are normalized together. We have used global normalization based on weighted average. The Ratio Builder was used calculate ratio probabilities for the differential expression among the control, 24h, and 28d groups. More detailed information on the Rosetta Resolver system Affymetix GeneChip error model, error-weighted statistical model, and ratio building error model can be found at Rosetta Resolver web site and in publications of Hughes et al. [45, 46]. As a result of analysis, genes were assigned p-values reflecting differences between the control and injected groups. The p-values were used to select genes for further clustering and functional classification. Thus, the analysis of data was based on the combination of two procedures: Resolver error model and self-organizing map (SOM) clustering complemented by functional classification using DAVID . We have used Affy chip background since more specific list of gene related to spinal cord expression is not available. SOM was applied by the weighted pair-group method with centered average and Pearson correlation implemented in the program xCluster (kindly provided by Gavin Sherlock, Stanford University). The differentially expressed genes were clustered according to their expression in 24h and 28d groups. Statistical differences within cluster were evaluated with one way ANOVA followed by Scheffe test. At the next step, the same genes differentially expressed at 28d and 24h were functionally classified by gene ontology. We also clustered genes known to be involved in inflammation using SOM. In order to organize selected genes according to the intracellular pathways involved, we used a context-based information search and graphical tools (GeneSphere, Malden, MA).
The selection of genes known to be involved in pain perception (Table 3) was based on gene ontology and a context-based information search of PubMed-indexed publications using the following criteria: a. protein involved in pain-related pathways; b. gene expression altered in different pain model; c. interaction with protein involved in pain (Table 4).
Sequence of primers for PCR verification.
CAG CCA AGG ACT TTA TTG ACC
GTC GCA CGT AAT CTT TAG CAA C
GAG AAG CTG GAA CGC ATA TAA G
GGG CTA CTT CAG CTT CGA AT
CAC TGG AAC CCG AAG TAT AAC A
CGC CTT TCT CCC GTC CTA
CAA GCC CCC GGT AGC AAA G
TGA CCG GCG TTG ATG GTA AGA T
AGC CAA GAC AGA TAG CCA TAC A
AAG CAG AGT GCC AGG TAG AAG
CGC TCT TCC CGG ACG AG
CCA CCA CAA GCC CAA GGA TAG G
ACT TCA AAG TCA CCC TGT ACG G
ATC CCA GTC AGC CAC GCT CAC
TCA GGG CAG TGG ACA GCG AAT A
AGC ACC GGC AGA ACG AC
CGG GAG AAG AAA GAG CTA CTG T
GGG CTG TTG TAG GTG TAC TGT C
GGC CCT GGA TGT AAT AGT GTC
GCC CTC AAA GAA TTC ATT GCA C
We appreciate the help from Cristina Freitas with our behavioral experiments.
This study was supported by an NIH R01 to I. Kissin.
- Kehlet H, Jensen TS, Woolf CJ: Persistent postsurgical pain: risk factors and prevention. Lancet. 2006, 367: 1618-1625. 10.1016/S0140-6736(06)68700-X.View ArticlePubMedGoogle Scholar
- Tasmuth T, Estlanderb AM, Kalso E: Effect of present pain and mood on the memory of past postoperative pain in women treated surgically for breast cancer. Pain. 1996, 68: 343-347. 10.1016/S0304-3959(96)03219-8.View ArticlePubMedGoogle Scholar
- Katz J, Jackson M, Kavanagh BP, Sandler AN: Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. Clin J Pain. 1996, 12: 50-55. 10.1097/00002508-199603000-00009.View ArticlePubMedGoogle Scholar
- Callesen T, Bech K, Kehlet H: Prospective study of chronic pain after groin hernia repair. Br J Surg. 1999, 86: 1528-1531. 10.1046/j.1365-2168.1999.01320.x.View ArticlePubMedGoogle Scholar
- Guilbaud G, Kayser V, Attal N, Benoist J-M: Evidence for a central contribution to secondary hyperalgesia. Hyperalgesia and Allodynia. Edited by: Willis WD. 1992, New York: Raven Press, 187-201.Google Scholar
- Aley KO, Messing RO, Mochly-Rosen D, Levine JD: Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C. J Neurosci. 2000, 20: 4680-4685.PubMedGoogle Scholar
- Kissin I, Freitas CF, Bradley ELJ: Memory of pain: the effect of perineural resiniferatoxin. Anesth Analg. 2006, 103: 721-728. 10.1213/01.ane.0000230604.00934.a1.View ArticlePubMedGoogle Scholar
- Wang H, Sun H, Della PK, Benz RJ, Xu J, Gerhold DL, et al: Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience. 2002, 114: 529-546. 10.1016/S0306-4522(02)00341-X.View ArticlePubMedGoogle Scholar
- Rodriguez PJ, Korostynski M, Kaminska-Chowaniec D, Obara I, Mika J, Przewlocka B, et al: Comparison of gene expression profiles in neuropathic and inflammatory pain. J Physiol Pharmacol. 2006, 57: 401-414.Google Scholar
- Costigan M, Befort K, Karchewski L, Griffin RS, D'Urso D, Allchorne A, et al: Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci. 2002, 3: 16-10.1186/1471-2202-3-16.PubMed CentralView ArticlePubMedGoogle Scholar
- Loguinov A, Anderson L, Crosby GJ, Yukhananov RY: Gene expression following acute administration of morphine. Physiological Genomics. 2001, 6: 169-181.PubMedGoogle Scholar
- Morey JS, Ryan JC, Van Dolah FM: Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online. 2006, 8: 175-193. 10.1251/bpo126.PubMed CentralView ArticlePubMedGoogle Scholar
- Obata K, Noguchi K: BDNF in sensory neurons and chronic pain. Neurosci Res. 2006, 55: 1-10. 10.1016/j.neures.2006.01.005.View ArticlePubMedGoogle Scholar
- Sjostrand C, Duvefelt K, Steinberg A, Remahl IN, Waldenlind E, Hillert J: Gene expression profiling in cluster headache: a pilot microarray study. Headache. 2006, 46: 1518-1534. 10.1111/j.1526-4610.2006.00611.x.View ArticlePubMedGoogle Scholar
- Kim DS, Lee SJ, Park SY, Yoo HJ, Kim SH, Kim KJ, et al: Differentially expressed genes in rat dorsal root ganglia following peripheral nerve injury. Neuroreport. 2001, 12: 3401-3405. 10.1097/00001756-200110290-00050.View ArticlePubMedGoogle Scholar
- Sun T, Xiao HS, Zhou PB, Lu YJ, Bao L, Zhang X: Differential expression of synaptoporin and synaptophysin in primary sensory neurons and up-regulation of synaptoporin after peripheral nerve injury. Neuroscience. 2006, 141: 1233-1245. 10.1016/j.neuroscience.2006.05.010.View ArticlePubMedGoogle Scholar
- Goswami C, Dreger M, Jahnel R, Bogen O, Gillen C, Hucho F: Identification and characterization of a Ca2+-sensitive interaction of the vanilloid receptor TRPV1 with tubulin. J Neurochem. 2004, 91: 1092-1103. 10.1111/j.1471-4159.2004.02795.x.View ArticlePubMedGoogle Scholar
- Lee MJ, Stephenson DA, Groves MJ, Sweeney MG, Davis MB, An SF, et al: Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4) gene. Hum Mol Genet. 2003, 12: 1917-1925. 10.1093/hmg/ddg198.View ArticlePubMedGoogle Scholar
- Abe T, Matsumura S, Katano T, Mabuchi T, Takagi K, Xu L, et al: Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. Eur J Neurosci. 2005, 22: 1445-1454. 10.1111/j.1460-9568.2005.04340.x.View ArticlePubMedGoogle Scholar
- De Jongh RF, Vissers KC, Meert TF, Booij LH, De Deyne CS, Heylen RJ: The role of interleukin-6 in nociception and pain. Anesth Analg. 2003, 96: 1096-103. 10.1213/01.ANE.0000055362.56604.78. tableView ArticlePubMedGoogle Scholar
- Verri WAJ, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH: Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?. Pharmacol Ther. 2006, 112: 116-138. 10.1016/j.pharmthera.2006.04.001.View ArticlePubMedGoogle Scholar
- Schafer M: Cytokines and peripheral analgesia. Adv Exp Med Biol. 2003, 521: 40-50.PubMedGoogle Scholar
- Song G, Cechvala C, Resnick DK, Dempsey RJ, Rao VL: GeneChip analysis after acute spinal cord injury in rat. J Neurochem. 2001, 79: 804-815. 10.1046/j.1471-4159.2001.00626.x.View ArticlePubMedGoogle Scholar
- Wang CX, Nuttin B, Heremans H, Dom R, Gybels J: Production of tumor necrosis factor in spinal cord following traumatic injury in rats. J Neuroimmunol. 1996, 69: 151-156. 10.1016/0165-5728(96)00080-X.View ArticlePubMedGoogle Scholar
- Bartholdi D, Schwab ME: Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci. 1997, 9: 1422-1438. 10.1111/j.1460-9568.1997.tb01497.x.View ArticlePubMedGoogle Scholar
- Khanapure SP, Garvey DS, Janero DR, Letts LG: Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007, 7: 311-340. 10.2174/156802607779941314.View ArticlePubMedGoogle Scholar
- Woolf CJ, Salter MW: Neuronal plasticity: increasing the gain in pain. Science. 2000, 288: 1765-1769. 10.1126/science.288.5472.1765.View ArticlePubMedGoogle Scholar
- Guo W, Zou S, Guan Y, Ikeda T, Tal M, Dubner R, et al: Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia. J Neurosci. 2002, 22: 6208-6217.PubMedGoogle Scholar
- Ko SW, Vadakkan KI, Ao H, Gallitano-Mendel A, Wei F, Milbrandt J, et al: Selective contribution of Egr1 (zif/268) to persistent inflammatory pain. J Pain. 2005, 6: 12-20. 10.1016/j.jpain.2004.10.001.View ArticlePubMedGoogle Scholar
- Noguchi K, Kowalski K, Traub R, Solodkin A, Iadarola MJ, Ruda MA: Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Brain Res Mol Brain Res. 1991, 10: 227-233. 10.1016/0169-328X(91)90065-6.View ArticlePubMedGoogle Scholar
- Dubner R, Ruda MA: Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 1992, 15: 96-103. 10.1016/0166-2236(92)90019-5.View ArticlePubMedGoogle Scholar
- Ji RR, Zhang X, Wiesenfeld-Hallin Z, Hokfelt T: Expression of neuropeptide Y and neuropeptide Y (Y1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J Neurosci. 1994, 14: 6423-6434.PubMedGoogle Scholar
- Ji RR: Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr Drug Targets Inflamm Allergy. 2004, 3: 299-303. 10.2174/1568010043343804.View ArticlePubMedGoogle Scholar
- Obata K, Noguchi K: MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci. 2004, 74: 2643-2653. 10.1016/j.lfs.2004.01.007.View ArticlePubMedGoogle Scholar
- Vadakkan KI, Wang H, Ko SW, Zastepa E, Petrovic MJ, Sluka KA, et al: Genetic reduction of chronic muscle pain in mice lacking calcium/calmodulin-stimulated adenylyl cyclases. Mol Pain. 2006, 2: 7-10.1186/1744-8069-2-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C: Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells. Int J Cancer. 2007, 120: 1652-1656. 10.1002/ijc.22407.PubMed CentralView ArticlePubMedGoogle Scholar
- Neugebauer V: Metabotropic glutamate receptors–important modulators of nociception and pain behavior. Pain. 2002, 98: 1-8. 10.1016/S0304-3959(02)00140-9.View ArticlePubMedGoogle Scholar
- De Blasi A, Conn PJ, Pin J, Nicoletti F: Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol Sci. 2001, 22: 114-120. 10.1016/S0165-6147(00)01635-7.View ArticlePubMedGoogle Scholar
- Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E: Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001, 410: 372-376. 10.1038/35066584.View ArticlePubMedGoogle Scholar
- Sandkuhler J: Understanding LTP in pain pathways. Mol Pain. 2007, 3: 9-10.1186/1744-8069-3-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Bailey CH, Bartsch D, Kandel ER: Toward a molecular definition of long-term memory storage. Proc Natl Acad Sci USA. 1996, 93: 13445-13452. 10.1073/pnas.93.24.13445.PubMed CentralView ArticlePubMedGoogle Scholar
- Groth R, Aanonsen L: Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB, prevent inflammation-induced hyperalgesia. Pain. 2002, 100: 171-181. 10.1016/S0304-3959(02)00264-6.View ArticlePubMedGoogle Scholar
- Chien CC, Fu WM, Huang HI, Lai YH, Tsai YF, Guo SL, et al: Expression of neurotrophic factors in neonatal rats after peripheral inflammation. J Pain. 2007, 8: 161-167. 10.1016/j.jpain.2006.07.004.View ArticlePubMedGoogle Scholar
- Meikle AD, Martin AH: A rapid method for removal of the spinal cord. Stain Technology. 1981, 56: 235-237.PubMedGoogle Scholar
- Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, et al: Functional discovery via a compendium of expression profiles. Cell. 2000, 102: 109-126. 10.1016/S0092-8674(00)00015-5.View ArticlePubMedGoogle Scholar
- Roberts CJ, Nelson B, Marton MJ, Stoughton R, Meyer MR, Bennett HA, et al: Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. Science. 2000, 287: 873-880. 10.1126/science.287.5454.873.View ArticlePubMedGoogle Scholar
- Dennis GJ, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 1907, 4: 3-10.1186/gb-2003-4-5-p3.View ArticleGoogle Scholar
- Okamoto K, Imbe H, Morikawa Y, Itoh M, Sekimoto M, Nemoto K, et al: 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. Pain. 2002, 99: 133-143. 10.1016/S0304-3959(02)00070-2.View ArticlePubMedGoogle Scholar
- Wu S, Zhu M, Wang W, Wang Y, Li Y, Yew DT: Changes of the expression of 5-HT receptor subtype mRNAs in rat dorsal root ganglion by complete Freund's adjuvant-induced inflammation. Neurosci Lett. 2001, 307: 183-186. 10.1016/S0304-3940(01)01946-2.View ArticlePubMedGoogle Scholar
- Dickinson T, Fleetwood-Walker SM: VIP and PACAP: very important in pain?. Trends Pharmacol Sci. 1999, 20: 324-329. 10.1016/S0165-6147(99)01340-1.View ArticlePubMedGoogle Scholar
- Wiesenfeld-Hallin Z, Xu XJ, Crawley JN, Hokfelt T: Galanin and spinal nociceptive mechanisms: recent results from transgenic and knock-out models. Neuropeptides. 2005, 39: 207-210. 10.1016/j.npep.2004.12.017.View ArticlePubMedGoogle Scholar
- Brumovsky P, Shi TS, Landry M, Villar MJ, Hokfelt T: Neuropeptide tyrosine and pain. Trends Pharmacol Sci. 2007, 28: 93-102. 10.1016/j.tips.2006.12.003.View ArticlePubMedGoogle Scholar
- Martin TJ, Eisenach JC, Misler J, Childers SR: Chronic activation of spinal adenosine A1 receptors results in hypersensitivity. Neuroreport. 2006, 17: 1619-1622. 10.1097/01.wnr.0000239949.37825.e9.View ArticlePubMedGoogle Scholar
- Sarret P, Esdaile MJ, Perron A, Martinez J, Stroh T, Beaudet A: Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J Neurosci. 2005, 25: 8188-8196. 10.1523/JNEUROSCI.0810-05.2005.View ArticlePubMedGoogle Scholar
- Lai J, Ossipov MH, Vanderah TW, Malan TPJ, Porreca F: Neuropathic pain: the paradox of dynorphin. Mol Interv. 2001, 1: 160-167. 10.1159/000048954.PubMedGoogle Scholar
- Miki K, Fukuoka T, Tokunaga A, Noguchi K: Calcitonin gene-related peptide increase in the rat spinal dorsal horn and dorsal column nucleus following peripheral nerve injury: up-regulation in a subpopulation of primary afferent sensory neurons. Neuroscience. 1998, 82: 1243-1252. 10.1016/S0306-4522(97)00258-3.View ArticlePubMedGoogle Scholar
- Bleakman D, Alt A, Nisenbaum ES: Glutamate receptors and pain. Semin Cell Dev Biol. 2006, 17: 592-604. 10.1016/j.semcdb.2006.10.008.View ArticlePubMedGoogle Scholar
- Smith PA, Moran TD, Abdulla F, Tumber KK, Taylor BK: Spinal mechanisms of NPY analgesia. Peptides. 2007, 28: 464-474. 10.1016/j.peptides.2006.09.029.View ArticlePubMedGoogle Scholar
- Ocana M, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM: Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol. 2004, 500: 203-219. 10.1016/j.ejphar.2004.07.026.View ArticlePubMedGoogle Scholar
- Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, et al: The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain. 2006, 7: S1-29. 10.1016/j.jpain.2006.01.444.View ArticlePubMedGoogle Scholar
- Sandelin M, Zabihi S, Liu L, Wicher G, Kozlova EN: Metastasis-associated S100A4 (Mts1) protein is expressed in subpopulations of sensory and autonomic neurons and in Schwann cells of the adult rat. J Comp Neurol. 2004, 473: 233-243. 10.1002/cne.20115.View ArticlePubMedGoogle Scholar
- Dale CS, Pagano RL, Paccola CC, Pinotti-Guirao T, Juliano MA, Juliano L, et al: Effect of the C-terminus of murine S100A9 protein on experimental nociception. Peptides. 2006, 27: 2794-2802. 10.1016/j.peptides.2006.07.002.View ArticlePubMedGoogle Scholar
- Mineta Y, Koyanagi H, Morimoto M, Harano K, Totoki T, Jacobowitz DM: Immunocytochemical study of parvalbumin, calbindin D-28k, and calretinin in the superficial dorsal horn of the rat spinal cord following unilateral hindpaw inflammation. J Anesthesia. 1996, 10: 211-217. 10.1007/BF02471393.View ArticleGoogle Scholar
- Traynor JR, Neubig RR: Regulators of G protein signaling & drugs of abuse. Mol Interv. 2005, 5: 30-41. 10.1124/mi.5.1.7.View ArticlePubMedGoogle Scholar
- Liu B, Zhang C, Qin F: Functional recovery from desensitization of vanilloid receptor TRPV1 requires resynthesis of phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005, 25: 4835-4843. 10.1523/JNEUROSCI.1296-05.2005.View ArticlePubMedGoogle Scholar
- Bedard A, Tremblay P, Chernomoretz A, Vallieres L: Identification of genes preferentially expressed by microglia and upregulated during cuprizone-induced inflammation. Glia. 2007, 55: 777-789. 10.1002/glia.20477.View ArticlePubMedGoogle Scholar
- Narita M, Ohsawa M, Mizoguchi H, Aoki T, Suzuki T, Tseng LF: Role of the phosphatidylinositol-specific phospholipase C pathway in delta-opioid receptor-mediated antinociception in the mouse spinal cord. Neuroscience. 2000, 99: 327-331. 10.1016/S0306-4522(00)00202-5.View ArticlePubMedGoogle Scholar
- Xie Z, Li Z, Guo L, Ye C, Li J, Yu X, et al: Regulator of G protein signaling proteins differentially modulate signaling of mu and delta opioid receptors. Eur J Pharmacol. 2007, 565: 45-53. 10.1016/j.ejphar.2007.03.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Martini L, Waldhoer M, Pusch M, Kharazia V, Fong J, Lee JH, et al: Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J. 2007, 21: 802-811. 10.1096/fj.06-7132com.View ArticlePubMedGoogle Scholar
- Cunha FQ, Teixeira MM, Ferreira SH: Pharmacological modulation of secondary mediator systems–cyclic AMP and cyclic GMP–on inflammatory hyperalgesia. Br J Pharmacol. 1999, 127: 671-678. 10.1038/sj.bjp.0702601.PubMed CentralView ArticlePubMedGoogle Scholar
- Durham P, Russo A: New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol Ther. 2002, 94: 77-92. 10.1016/S0163-7258(02)00173-0.View ArticlePubMedGoogle Scholar
- Zhang X, Wu J, Fang L, Willis WD: The effects of protein phosphatase inhibitors on nociceptive behavioral responses of rats following intradermal injection of capsaicin. Pain. 2003, 106: 443-451. 10.1016/j.pain.2003.09.002.View ArticlePubMedGoogle Scholar
- Bron R, Klesse LJ, Shah K, Parada LF, Winter J: Activation of Ras is necessary and sufficient for upregulation of vanilloid receptor type 1 in sensory neurons by neurotrophic factors. Mol Cell Neurosci. 2003, 22: 118-132. 10.1016/S1044-7431(02)00022-2.View ArticlePubMedGoogle Scholar
- Ishii DN: Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Brain Res Rev. 1995, 20: 47-67. 10.1016/0165-0173(94)00005-A.View ArticlePubMedGoogle Scholar
- Lacroix-Fralish ML, Tawfik VL, Nutile-McMenemy N, DeLeo JA: Neuregulin 1 is a pronociceptive cytokine that is regulated by progesterone in the spinal cord: Implications for sex specific pain modulation. Eur J Pain. 2007Google Scholar
- Sommer C, Kress M: Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004, 361: 184-187. 10.1016/j.neulet.2003.12.007.View ArticlePubMedGoogle Scholar
- Zeilhofer HU: Prostanoids in nociception and pain. Biochem Pharmacol. 2007, 73: 165-174. 10.1016/j.bcp.2006.07.037.View ArticlePubMedGoogle Scholar
- Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A, et al: Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA. 1999, 96: 726-730. 10.1073/pnas.96.2.726.PubMed CentralView ArticlePubMedGoogle Scholar
- Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, et al: Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007, 27: 6006-6018. 10.1523/JNEUROSCI.0176-07.2007.PubMed CentralView ArticlePubMedGoogle Scholar
- Moss A, Blackburn-Munro G, Garry EM, Blakemore JA, Dickinson T, Rosie R, et al: A role of the ubiquitin-proteasome system in neuropathic pain. J Neurosci. 2002, 22: 1363-1372.PubMedGoogle Scholar
- Yamanaka H, Obata K, Kobayashi K, Dai Y, Fukuoka T, Noguchi K: Alteration of the cell adhesion molecule L1 expression in a specific subset of primary afferent neurons contributes to neuropathic pain. Eur J Neurosci. 2007, 25: 1097-1111. 10.1111/j.1460-9568.2007.05344.x.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.